Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(1 site)
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Age range
18 Years and older
Last updated December 2024